Low-dose Y90 Treatment Planning for HCC

Sponsor

Emory University (Other)

Overall Status

Completed

CT.gov ID

NCT04172714

Collaborator

(none)

Enrollment

Locations

Arm

18.5

Actual Duration (Months)

10.3

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study proposes low-dose Y90 microspheres for therapy planning of HCC, as an alternative to Technetium (99mTc) albumin aggregated (MAA), to be a bioidentical therapeutic Y90 surrogate marker to better predict and thus achieve optimal therapeutic dosing.

Condition or Disease	Intervention/Treatment	Phase
HCC Cancer of Liver Cancer	Device: SIR-Spheres microspheres	N/A

Detailed Description

Hepatocellular carcinoma is a second deadliest cancer in the world with less than 20% of patients eligible for curative surgery at the time of diagnosis. Yttrium-90 (Y90) radioembolization is palliative treatment with promising result. However, one of the most important factors in the success of Y90 treatment is to ensure adequate dose of radioactive material is delivered to the tumor. The technetium-99 macroaggregated albumin (MAA) which is currently used for Y90 treatment planning and shunt study does not predict distribution of Y90 in the lungs, tumors, and liver. Therefore, accurate and personalized treatment planning cannot be performed using MAA. In this study, we are proposing using low-dose Y90 microspheres for the planning stage of the therapy to obtain an accurate estimation of distribution of Y90 therapy dose. This will in turn allow us to ensure adequate dose of Y90 is delivered to the tumor(s) while minimizing dose delivered to non-tumor liver and lungs in order to decrease the chance of treatment related toxicity to the liver and lungs.

Study Design

Study Type:

Interventional

Actual Enrollment :

31 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Theragnostic Low Dose Y90 Microspheres for Personalized Y90 Radioembolization Dosimetry Planning

Actual Study Start Date :

Dec 16, 2019

Actual Primary Completion Date :

Jun 30, 2021

Actual Study Completion Date :

Jun 30, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Second mapping with low-dose Y90 Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.	Device: SIR-Spheres microspheres SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days. Other Names: SIRSPHERE Y90 resin-based microspheres

Arm

Intervention/Treatment

Experimental: Second mapping with low-dose Y90

Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.

Device: SIR-Spheres microspheres

SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.

Other Names:

SIRSPHERE

Y90 resin-based microspheres

Outcome Measures

Primary Outcome Measures

Change in Lung shunt fraction (LSF) [Baseline, 1 month postintervention, 3 months post intervention, 6 months post intervention]
Y-90 radioembolization treatment requires estimating the activity shunted from the liver to the lungs, referred to as a lung shunt fraction (LSF). It is expressed in percentage, with higher percentage meaning a higher transit of Y-90 to the lungs (worse outcome) and lower percentage, lower transit of Y-90 to the lungs (better outcome).
Change in tumor to normal liver activity ration (TNR) [Baseline, 1 month postintervention, 3 months post intervention, 6 months post intervention]
The ratios of the tumor-to-normal liver parenchymal radioactivity uptake count will be measured. TNR values will be calculated by dividing the mean count of the tumorous volume of interest (VOI) by the mean count of normal liver.

Secondary Outcome Measures

Change in Y90 related toxicity [Baseline, 1 month postintervention, 3 months post intervention, 6 months post intervention]
Adverse events related to Y90 radioembolization and angiography will be document by physical examination, clinical laboratory test and cross-sectional imaging.
Change in Tumor response using Imaging Modified Response Criteria in Solid Tumors (m-RECIST) post Y90 embolization [Baseline, 1 month postintervention, 3 months post intervention, 6 months post intervention]
To identify tumor dose response threshold (TDRT) using Imaging Modified Response Criteria in Solid Tumors (m-RECIST), that is a method for measuring treatment response and measure of antitumor activity of cytotoxic drugs. This is measured using imaging: CT or MRI. The overall response is a combination of responses in each category: complete response (disappearance of any intramural arterial enhancement in all target lesions), partial response (at least 30% decrease in the sum of the diameters of viable target lesions), stable disease (any cases that do not qualify for either partial response or progressive disease) or progressive disease (an increase of at least 20% in the sum of the diameters of viable, enhancing target lesions, taking as a reference the smallest sum of the diameters of viable target lesions recorded since treatment started).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adults ≥ 18 years
Life expectancy of 6 months or more as determined by the investigator
HCC confirmed by Liver Reporting & Data System (LIRADS) on MRI or CT
Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) with CT scan, MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.
≤3 lesions
Longest dimension of the largest lesion ≤7cm
Single lobe disease
No significant extrahepatic metastatic disease
Barcelona Clinic Liver Cancer Stage A, B or C
ECOG < 2 (Appendix A)
Lesion(s) <50% of liver volume
Bilirubin ≤ 2 mg/dL
Albumin ≥ 3 g/dL
PT/INR < 2
AST/ALT ≤ 3 institutional upper limit of normal (ULN)
Platelet count > 50,000/mcL
Lung shunt fraction of <20% by planar MAA if dose modification results in inadequate dose delivered to the tumor(s)
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥ 12 week before the start of study therapy. Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.

Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation. v. The effects of Y90 microspheres on the developing human fetus are unknown. For this reason female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. Winship Protocol #: RAD4784 Version Date: Aug 22, 2019 20 | P a g e w. FCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of [IND Agent] administration. A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months

Exclusion Criteria:

An individual who does not meet all the inclusion criteria in section.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Emory University Midtown	Atlanta	Georgia	United States	30308
2	Emory Clinic	Atlanta	Georgia	United States	30322
3	Emory University Hospital	Atlanta	Georgia	United States	30322